TY  - THES
N2  - Lutetium-177 vipivotide tetraxetan (Lu-177 PSMA-617) therapy is an effective treatment for patients with metastatic prostate cancer, although with potential adverse effects to the kidneys, salivary glands, and bone marrow. As a preventative measure for atrisk patients, dosimetry using four SPECT/CT scans is performed with the first cycle of Lu177 therapy. In this work, seven Lu-177 PSMA-617 dosimetry cases from patients treated at Oregon Health & Science University with SPECT scans taken at 4 hours, 24 hours, 48 hours, and 72 hours post-injection  were retrospectively analyzed for how omitting each of the scans in performing dosimetry would affect reported absorbed doses to the kidneys, liver, lungs, parotid glands, and tumor.
DO  - 10.6083/bpxhc43397
DO  - doi
AB  - Lutetium-177 vipivotide tetraxetan (Lu-177 PSMA-617) therapy is an effective treatment for patients with metastatic prostate cancer, although with potential adverse effects to the kidneys, salivary glands, and bone marrow. As a preventative measure for atrisk patients, dosimetry using four SPECT/CT scans is performed with the first cycle of Lu177 therapy. In this work, seven Lu-177 PSMA-617 dosimetry cases from patients treated at Oregon Health & Science University with SPECT scans taken at 4 hours, 24 hours, 48 hours, and 72 hours post-injection  were retrospectively analyzed for how omitting each of the scans in performing dosimetry would affect reported absorbed doses to the kidneys, liver, lungs, parotid glands, and tumor.
AD  - Oregon Health and Science University
T1  - Effect of reducing imaging time points in lutetium-177 vipivotide tetraxetan dosimetry
ED  - Winters, Celeste
ED  - Advisor
DA  - 2024-06-14
AU  - Dodson, Evan
L1  - https://digitalcollections.ohsu.edu/record/43397/files/Dodson.Evan.2024.pdf
PB  - Oregon Health and Science University
LA  - eng
PY  - 2024-06-14
ID  - 43397
L4  - https://digitalcollections.ohsu.edu/record/43397/files/Dodson.Evan.2024.pdf
KW  - Single Photon Emission Computed Tomography Computed Tomography
KW  - Radiopharmaceuticals
KW  - Drug Therapy, Computer-Assisted
KW  - Radiometry
KW  - Nuclear Medicine
KW  - SPECT
KW  - PLUVICTO
TI  - Effect of reducing imaging time points in lutetium-177 vipivotide tetraxetan dosimetry
Y1  - 2024-06-14
L2  - https://digitalcollections.ohsu.edu/record/43397/files/Dodson.Evan.2024.pdf
LK  - https://digitalcollections.ohsu.edu/record/43397/files/Dodson.Evan.2024.pdf
UR  - https://digitalcollections.ohsu.edu/record/43397/files/Dodson.Evan.2024.pdf
ER  -